CPT code 83013 designates a noninvasive breath test that detects an isotope marker of Helicobacter pylori infection, an organism linked to gastritis and peptic ulcer disease. As a laboratory diagnostic procedure, this code is important nationally because it supports targeted management of patients with dyspepsia and suspected H. pylori, informs antibiotic treatment decisions, and can reduce the need for more invasive testing.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the assay, common payer coverage considerations, and typical sites of service. The publication outlines what providers and administrators need to know about CPT code 83013 without offering clinical recommendations: its clinical purpose, where the test is ordinarily performed, and typical billing patterns.

The report also summarizes available benchmarking and reimbursement context where provided, highlights relevant policy updates affecting laboratory diagnostics generally, and clarifies areas where data was not available in the input. This material is intended for national audiences including lab managers, billing staff, and policy analysts seeking a clear operational and coding-focused overview of CPT code 83013.